Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

Open access
Leong, Darryl P., Caron, François, Hillis, Christopher, Duan, Annie, Healey, Jeff S., Fraser, Graeme, Siegal, Deborah·2016·Blood

Abstract

Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase in the B-cell receptor signaling pathway.In randomized trials, ibrutinib is effective as first-line treatment of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) (compared with chlorambucil), 1 for relapsed/refractory CLL/SLL (compared with ofatumumab or combined with bendamustine/rituximab), 2,3 or for relapsed/refractory mantle cell lymphoma (compared with temsiroliums), 4 with promising results in the treatment of Waldenström macroglobulinemia.5 It is anticipated that ibrutinib will become an important part of the therapeutic armamentarium for these conditions.Randomized trials suggest that ibrutinib may increase the risk of atrial fibrillation (AF) as compared with chlorambucil 1 or ofatumumab. 2 In the general population, AF is strongly associated with heart failure and arterial thromboembolism, which result in substantial morbidity and mortality.There is uncertainty over the magnitude of the increase in AF risk attributable to ibrutinib because the absolute numbers of incident AF cases are small in individual studies.We undertook a systematic review and meta-analysis to ( 1) estimate the magnitude of the increase in AF risk among ibrutinib recipients, as compared with alternative therapies and (2) quantify the frequency of AF reported among ibrutinib recipients.We searched MEDLINE and EMBASE, and proceedings from the American Society of Hematology, the European Haematology Association, and the American Society of Clinical Oncology for articles describing AF rates in recipients of ibrutinib.The following search terms were used: ibrutinib; imbruvica; or PCI-32765.Animal studies, case reports, case series (ie, that reported on consecutive AF cases), cross-sectional studies, editorials, phase I/dose-finding studies, and conference abstracts more than 12 months old were excluded.Two independent reviewers screened the articles' titles and abstracts for eligibility.Cases of disagreement were resolved by a third reviewer.Papers identified after title and abstract screening were obtained in full.When data from the same cohort of participants were presented in different papers, only the manuscript with the larger sample size was included in the meta-analysis.The following data were extracted from eligible full text manuscripts: design, disease, sample size, treatments, participant age and sex, follow-up duration, AF rates, and where reported, AF ascertainment strategies, past history of cardiovascular disease, AF, or hypertension.Statistical analysis was performed using STATA 14 (StataCorp, College Station, TX).To evaluate the increase in the risk of incident AF, the primary meta-analytic approach was a fixed effects model using the Mantel-Haenszel method.A sensitivity analysis was performed using a DerSimonian and Laird random effects model.Heterogeneity of studies was evaluated by Cochran's Q and the I 2 statistic.Pooled AF rates were estimated as follows: we multiplied the median follow-up duration by the sample size.Crude study-specific AF rates were then

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-05-712828

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 233

Metadata

Authors
Leong, D. P., Caron, F., Hillis, C., Duan, A., Healey, J. S., Fraser, G., & Siegal, D.
Venue
Blood
Published
2016-07-07
Volume
128
Issue
1
Pages
138-140
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2464293395
Cited by
233
References
2
FWCI
6.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1182/blood-2016-05-712828
The paper
Leong, D. P., Caron, F., Hillis, C., Duan, A., Healey, J. S., Fraser, G., & Siegal, D. (2016). The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. https://doi.org/10.1182/blood-2016-05-712828

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.